Solen Therapeutics Adds Directors, Adjusts Executive Pay
Ticker: SLNO · Form: 8-K · Filed: Jul 19, 2024 · CIK: 1484565
| Field | Detail |
|---|---|
| Company | Soleno Therapeutics Inc (SLNO) |
| Form Type | 8-K |
| Filed Date | Jul 19, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, management-changes
TL;DR
Solen Therapeutics adds Rothberg & Singer to board, revises CEO/CFO pay packages.
AI Summary
Solen Therapeutics, Inc. announced on July 17, 2024, a change in its board of directors and executive compensation arrangements. Specifically, the company elected two new directors, Dr. Jonathan M. Rothberg and Mr. David E. Singer, to its Board of Directors, effective immediately. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Dr. Anca J. Groza, and its Chief Financial Officer, Mr. Jonathan P. Lim, detailing their compensation and severance packages.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board and executive compensation can introduce uncertainty regarding strategic direction and management stability.
Key Players & Entities
- Solen Therapeutics, Inc. (company) — Registrant
- Dr. Jonathan M. Rothberg (person) — Newly elected director
- Mr. David E. Singer (person) — Newly elected director
- Dr. Anca J. Groza (person) — Chief Executive Officer
- Mr. Jonathan P. Lim (person) — Chief Financial Officer
- July 17, 2024 (date) — Date of earliest event reported
FAQ
Who were the new directors elected to Solen Therapeutics' Board?
Dr. Jonathan M. Rothberg and Mr. David E. Singer were elected to the Board of Directors.
When were the changes to the Board of Directors effective?
The election of the new directors was effective immediately as of July 17, 2024.
Which executive officers entered into new employment agreements?
Dr. Anca J. Groza, the Chief Executive Officer, and Mr. Jonathan P. Lim, the Chief Financial Officer, entered into new employment agreements.
What is the principal executive office address for Solen Therapeutics?
The principal executive offices are located at 203 Redwood Shores Parkway, Suite 500, Redwood City, CA 94065.
What was the former name of Solen Therapeutics?
The former name of Solen Therapeutics was Capnia, Inc., with a date of name change on February 19, 2010.
Filing Stats: 726 words · 3 min read · ~2 pages · Grade level 14 · Accepted 2024-07-19 09:01:03
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value SLNO NASDAQ Indicate by
Filing Documents
- d839231d8k.htm (8-K) — 28KB
- 0001193125-24-181329.txt ( ) — 148KB
- slno-20240717.xsd (EX-101.SCH) — 3KB
- slno-20240717_lab.xml (EX-101.LAB) — 18KB
- slno-20240717_pre.xml (EX-101.PRE) — 11KB
- d839231d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SOLENO THERAPEUTICS, INC. Date: July 19, 2024 By: /s/ Anish Bhatnagar Anish Bhatnagar Chief Executive Officer 3